Press release

Gubra strengthens board and top management

Hørsholm, Denmark 14 June 2018

Gubra has experienced a very positive development for a number of years and to keep evolving, Gubra has decided to expand the board and top management inducing additional business and technological competencies.

At the annual general meeting in May 2018, Poul Hæstrup was elected as new member of the Board. Poul has vast experience with business transformation, strategy and organisational development, and his set of competencies will be a very valuable addition to the Gubra Board. Poul is senior partner in the management consultancy company Implement. “Gubra is an extremely dynamic and fast paced company with an immense potential. Their deeply rooted culture and entrepreneurial mindset, which permeate the entire organisation, is truly inspiring and I am very excited to be joining the Gubra Board being part of the journey going forward”, says Poul Hæstrup.

Further, Gubra has recently appointed Morten Høgholm Pedersen as Chief Technology Officer (CTO). Morten will focus on the further development of the customer-data-interface and how to gain even more valuable insights from data. Morten adds both technological and innovation capabilities to Gubra’s top management, and his proven entrepreneurial mindset will be a great asset for Gubra going forward.

Gubra has delivered yet another great result in 2017

2017 has been another year with progression on all key parameters. The business, which now comprise of +125 employees from all over the world, is solid and well performing. In 2017, Gubra greatly expanded the customer base and built even closer ties to customers through scientific counselling and close dialogue. Key data sharing and analysis tools have been launched which greatly improves data access and data integrity.
Gubra is recognized globally for state-of-the-art preclinical models. Our NASH services have again been a key growth driver, but also obesity, diabetes and model development efforts with diabetic complications (diabetic nephropathy and diabetic cardiomyopathy) have contributed significantly.

In 2017 Gubra finalized a successful four-year collaboration with Sanofi and begun a new collaboration with Boehringer Ingelheim – a partnership which also holds great potential for both parties. Gubra’s other internal programs have during the past year progressed well and we now have several programs ready for external partnering.

About Gubra ApS

Founded in 2008, Gubra is a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Gubra’s focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. For more information, please visit Gubra’s website at

Henrik Blou, CEO
Phone: +45 2861 6845